NCT/Study#
NCT06469281 /
27T51-01
A Phase 1a/1b Study of 27T51, an anti-MUC16 CAR T cell drug product administered alone or in combination for participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer
DISEASE GROUP:
CAR-T
current phase:
Phase I
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
